HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NCNA
NuCana plc
There isn't enough reported data to score NCNA yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NCNA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
NCNA's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NCNA PE Valuation
NCNA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NCNA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect NCNA's losses to grow, with revenue holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
NCNA has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus NCNA down 100%.
NCNA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2025 | -$1,857.47 | +$2,355.11 |
| Q4 2024 | -$2,797.37 | +$1,552.63 |
| Q3 2024 | -$3,964.14 | +$3,991.80 |
| Q2 2024 | -$4,388.55 | +$3,175.99 |
| Q1 2024 | -$4,212.58 | +$3,120.87 |
| Q4 2023 | -$4,350.00 | +$3,205.97 |
| Q3 2023 | -$7,955.94 | -$2,845.38 |
| Q2 2023 | -$7,564.54 | -$1,719.91 |
NCNA lost $3.95 per share over the past year, a smaller loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NCNA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
NCNA Quarterly Revenue
NCNA's revenue is shrinking: $0 last quarter.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over NCNA on cash generation, producing positive trailing cash flow while its opponent burns cash.
NCNA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.6M | +$3.5M |
| Q1 2026 | -$4.3M | -$147.7K |
| Q4 2025 | -$1.6M | +$8.4M |
| Q3 2025 | $1.6M | +$7.8M |
| Q2 2025 | -$6M | -$4.3M |
| Q1 2025 | -$4.2M | +$3.7M |
| Q4 2024 | -$10M | -$9.8M |
| Q3 2024 | -$6.2M | +$7.4M |
NCNA has burned cash in almost every quarter: −$7M over the past year, against −$26M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NCNA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NCNA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +23.8K shares |
| 1 year | +13687% | +4.2M shares |
| 3 years | +39858% | +4.2M shares |
| 5 years | +40423% | +4.2M shares |
| Available history | +64553% | +4.2M shares |
NCNA has 4M diluted shares, up 13687% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
NCNA hasn't bought back shares in the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NCNA Net Leverage
NCNA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NCNA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.6 | Neutral |
| Stochastic | 5.2 | Oversold |
NCNA's weekly RSI is 32 (neutral) and its Stochastic is 5 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NCNA PE vs Healthcare Sector
NCNA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NCNA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.04 | 11% below |
| 20 week MA | $1.27 | 27% below |
| 50 week MA | $1.96 | 53% below |
| 100 week MA | $42.1 | 98% below |
| 200 week MA | $1,248.8 | 100% below |
NCNA is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over NCNA on returns for 2026, with the stronger performance.
NCNA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $31,000.0 | $25,000.0 | -19% |
| 2021 | $25,000.0 | $12,350.0 | -51% |
| 2022 | $12,350.0 | $3,900.0 | -68% |
| 2023 | $3,900.0 | $1,480.0 | -62% |
| 2024 | $1,480.0 | $284.0 | -81% |
| 2025 | $284.0 | $3.31 | -99% |
| 2026 YTD | $3.31 | $0.93 | -72% |
NCNA has finished every year since 2020 lower, and it's down 72% so far in 2026.